European Biotechnology Guide 2022
The 12th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Catalent swallows VMIC Ltd
Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA launches €440 m private equity healthcare strategy
AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
Creating a safe ultra-low cold storage environment
In recent years, several beneficial cell samples and microbial strains have been discovered, engineered, and studied, resulting in scientific discoveries and other technological breakthroughs such as vaccines and medicines benefitting communities all around the world. However, several medical products tend to require very low temperatures for storage, making Ultra-Low Freezers increasingly important to maintain their viability.
Bayer Leaps to invests €1.3bn externally
German Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Avantium closes financing for FDCA plant
Avantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF.
Novo Holdings co-leads €40m Qure.ai financing
Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad
Sanofi and IGM Biosciences Inc. in $6.15bn deal
Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
XNK Therapeutics AB raises €12.75m
XNK Therapeutics AB has secured a private placement of €12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
Mastering the data revolution of clinical trials
Data Management has been a hotbed for development and innovation, correlating primarily with
the changing digital landscape. Clinical trial management has been significantly impacted, with the
electronic data capture and GDPR-compliance-led industry now unrecognisable from the paper-document administration methods of the past. This development process extends beyond COVID-19 and has a
noticeable impact on clinical trials.